The most innovative and accurate test to measure a major modifiable risk factor for Alzheimer’s disease.
The ALZ-1 Test is the most innovative and accurate test to measure one of the risk factors that contributes to the development and progression of Alzheimer’s disease. Through patented technology, concentrations of Non-Cp Copper, free circulating copper, can be quantified through a blood sample (WO214/071973A1).
Normal range is 0.5-1.9 micromoles /L. Patients who have a copper quantity above 1.9 µM have a risk of developing dementia that is three times higher compared to those with a copper quantity below 1.9 µM.
The ALZ-1 test is designed to prevent the onset of Alzheimers disease before it develops by reducing a prevalent risk factor. Patients who have high levels of Non-Cu Copper should consult with their physicians. A low copper diet and supplement regime increases the production of endogenous proteins which impact the storage of copper in the body. This valuable agent in the form of metallothionein, captures the circulating Non-Cp Copper, and forces its elimination, reducing its quantity and its toxicity.